Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/RCCM.200204-302OCPMID 12403688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper
• Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

  2001cited by this paper
• Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

  2001cited by this paper
• Clinical trials for severe sepsis. Past failures, and future hopes.

  1999cited by this paper
• An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials.

  1998cited by this paper
• Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.

  1998cited by this paper
• Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.

  1998cited by this paper
• Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

  1998cited by this paper
• Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial.

  1998cited by this paper
• Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment.

  1997cited by this paper
• Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.

  1997cited by this paper
• Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis.

  1997cited by this paper
• The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.

  1997cited by this paper
• p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.

  1997cited by this paper
• Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

  1997cited by this paper
• p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic Shock: A Randomized Controlled Multicenter Trial

  1997cited by this paper
• From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop.

  1997cited by this paper
• INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

  1996cited by this paper
• Anticytokine strategies for the treatment of septic shock: relevance of animal models.

  1996cited by this paper
• Reflecting and regrouping after failed trials, sepsis researchers forge on.

  1996cited by this paper
• Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli-induced lethal toxicity.

  1996cited by this paper
• Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

  1996cited by this paper
• Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group.

  1996cited by this paper
• Magnesium in acute myocardial infarction: Scientific, statistical, and economic rationale for its use

  1996cited by this paper
• Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis.

  1996cited by this paper
• Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

  1996cited by this paper
• Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats.

  1996cited by this paper
• Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

  1995cited by this paper
• Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: improved survival and organ function.

  1995cited by this paper
• CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.

  1995cited by this paper
• Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial

  1995cited by this paper
• Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit.

  1995cited by this paper
• 195 RESULTS OF A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CP-0127, A NOVEL BRADYKININ ANTAGONIST. IN PATIENTS WITH SIRS AND SEPSIS

  1995cited by this paper
• Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

  1994cited by this paper
• Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial

  1994cited by this paper
• Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors.

  1994cited by this paper
• Platelet‐activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial

  1994cited by this paper
• Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram- negative sepsis

  1994cited by this paper
• Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody.

  1994cited by this paper
• Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

  1994cited by this paper
• Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

  1994cited by this paper
• Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

  1993cited by this paper
• An Effect Model for the Assessment of Drug Benefit: Example of Antiarrhythmic Drugs in Postmyocardial Infarction Patients

  1993cited by this paper
• The efficacy of combination immunotherapy in experimental Pseudomonas sepsis.

  1993cited by this paper
• Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein‐tyrosine kinase activity

  1993cited by this paper
• Cholesterol lowering and mortality: the importance of considering initial level of risk.

  1993cited by this paper
• Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis

  1993cited by this paper
• Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials.

  1992cited by this paper
• Monoclonal antibody to tumor necrosis factor--alpha prevents lethal endotoxin sepsis in adult rhesus monkeys.

  1992cited by this paper
• Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

  1992cited by this paper
• Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody.

  1992cited by this paper
• Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine.

  1992cited by this paper
• Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

  1992cited by this paper
• Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia.

  1992cited by this paper
• CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock.

  1992cited by this paper
• Interleukin 1 and tumor necrosis factor activate common multiple protein kinases in human fibroblasts.

  1991cited by this paper
• Effect of ibuprofen in patients with severe sepsis: A randomized, double‐blind, multicenter study

  1991cited by this paper
• A specific receptor antagonist for interleukin 1 prevents Escherichia coli‐induced shock in rabbits

  1991cited by this paper
• Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide‐induced lethality

  1991cited by this paper
• Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition.

  1991cited by this paper
• Serum TNFα in mouse typhoid and enhancement of a salmonella infection by anti-TNFα antibodies

  1991cited by this paper
• Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.

  1991cited by this paper
• Serum TNF alpha in mouse typhoid and enhancement of a Salmonella infection by anti-TNF alpha antibodies.

  1991cited by this paper
• Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis.

  1991cited by this paper
• Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis.

  1991cited by this paper
• Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha).

  1990cited by this paper
• Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis.

  1990cited by this paper
• Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock.

  1990cited by this paper
• Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

  1990cited by this paper
• Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.

  1990cited by this paper
• Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.

  1990cited by this paper
• Antibiotics versus cardiovascular support in a canine model of human septic shock.

  1990cited by this paper
• Bacterial lipopolysaccharide priming of P388D1 macrophage-like cells for enhanced arachidonic acid metabolism. Platelet-activating factor receptor activation and regulation of phospholipase A2.

  1990cited by this paper
• Relationships between tumour necrosis factor, eicosanoids and platelet‐activating factor as mediators of endotoxin‐induced shock in mice

  1990cited by this paper
• Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

  1988cited by this paper
• Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

  1988cited by this paper
• Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

  1987cited by this paper
• Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.

  1987cited by this paper
• Inhibition of rat endotoxin-induced lethality by BN 52021 and BN 52063, compounds with PAF-acether antagonistic effect and protease-inhibitory activity.

  1987cited by this paper
• Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis.

  1987cited by this paper
• Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

  1987cited by this paper
• Statistical Methods for Meta-Analysis

  1987cited by this paper
• Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

  1985cited by this paper
• Ibuprofen in canine endotoxin shock.

  1982cited by this paper
• Ibuprofen improves survival from endotoxic shock in the rat.

  1980cited by this paper
• Indomethacin improves survival after endotoxin in baboons.

  1980cited by this paper
• MODIFICATION, BY ASPIRIN AND INDOMETHACIN, OF THE HAEMODYNAMIC AND PROSTAGLANDIN RELEASING EFFECTS OF E. coli ENDOTOXIN IN THE DOG

  1977cited by this paper
• E. coli ENDOTOXIN SHOCK IN THE CAT; TREATMENT WITH INDOMETHACIN

  1975cited by this paper
• The analysis of binary data

  1971cited by this paper

• Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal

  2025cites this paper
• Machine learning glucose forecasting models for septic patients

  2025cites this paper
• Unexpected Protective Role of Thrombosis in Lung Injury via Endothelial Alox15.

  2025cites this paper
• Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective

  2025cites this paper
• Immunotherapies for sepsis and the impact of study design

  2025cites this paper
• Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS)

  2025cites this paper
• Microglial activation and neuroinflammation in acute and chronic cognitive deficits in sepsis.

  2024cites this paper
• Shadows and lights in sepsis immunotherapy

  2024cites this paper
• The effect of polyclonal and monoclonal based antibodies as promising potential therapy for treatment of sepsis: A systematic review

  2024cites this paper
• Inhibition of cIAP1/2 reduces RIPK1 phosphorylation in pulmonary endothelial cells and alleviate sepsis-induced lung injury and inflammatory response

  2024cites this paper
• EMERGENCE OF A TECHNOLOGY-DEPENDENT PHENOTYPE OF PEDIATRIC SEPSIS IN A LARGE CHILDREN'S HOSPITAL

  2023cites this paper
• The Unexpected Protective Role of Thrombosis in Sepsis-Induced Inflammatory Lung Injury Via Endothelial Alox15

  2023cites this paper
• Ablation of myeloid discoidin domain receptor 2 exacerbates arthritis and high fat diet induced inflammation.

  2023cites this paper
• Identification of Clinical Phenotypes in Septic Patients Presenting With Hypotension or Elevated Lactate

  2022cites this paper
• Defining Sepsis Phenotypes—Two Murine Models of Sepsis and Machine Learning

  2022cites this paper
• CIITA promoter polymorphism impairs monocytes HLA-DR expression in patients with septic shock

  2022cites this paper
• Risk management after cardiopulmonary resuscitation—

  2022influential citation
• Machine learning and murine models explain failures of clinical sepsis trials

  2022cites this paper
• Olaparib attenuates sepsis-induced acute multiple organ injury via ERK-mediated CD14 expression

  2021cites this paper
• Chrysin Ameliorates Sepsis-Induced Cardiac Dysfunction Through Upregulating Nfr2/Heme Oxygenase 1 Pathway.

  2021cites this paper
• Esmolol to Treat the Hemodynamic Effects of Septic Shock: A Randomized Controlled Trial

  2021cites this paper
• Cytokines in sepsis: friend or enemy?

  2021cites this paper
• Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19

  2020cites this paper
• Cytokines in Inflammatory Disease

  2020cites this paper
• Resveratrol attenuates TLR-4 mediated inflammation and elicits therapeutic potential in models of sepsis

  2020cites this paper
• PhospholipaseCγ1/calcium-dependent membranous localization of Gsdmd-N drives endothelial pyroptosis, contributing to lipopolysaccharide-induced fatal outcome.

  2020cites this paper
• Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis

  2020cites this paper
• A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1β signaling interruption.

  2020cites this paper
• Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update.

  2020cites this paper
• The role of vagus nerve stimulation in sepsis

  2020cites this paper
• Incidence, trends, and outcomes of infection sites among hospitalizations of sepsis: A nationwide study

  2020cites this paper
• Epidemiology of Sepsis-3 in a sub-district of Beijing: secondary analysis of a population-based database

  2019cites this paper
• Premise for Standardized Sepsis Models.

  2019cites this paper
• Haptoglobin therapy has differential effects depending on severity of canine septic shock and cell‐free hemoglobin level

  2019cites this paper
• Clinical trial design for unmet clinical needs: a spotlight on sepsis

  2019cites this paper
• Anti-inflammatory, anti-oxidative stress effect of Phascolosoma esculenta oligosaccharides on Escherichia coli-induced sepsis mice

  2019cites this paper
• Comparison between MPO, CD177 and NF-κB Gene Expression of Septic Rats Treated with Mentha longifolia Essential Oils

  2019cites this paper
• Risk related therapy in meta-analyses of critical care interventions: Bayesian meta-regression analysis.

  2019cites this paper
• Linezolid and Its Immunomodulatory Effect: In Vitro and In Vivo Evidence

  2019cites this paper
• Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood

  2019cites this paper
• Cytokines in Inflammatory Disease

  2019cites this paper
• Risks and benefits of fluid bolus therapy: the need for a good explanation

  2019cites this paper
• The effects of Tumour necrosis factor-alpha and Interleukin-1-beta on intracellular calcium handling and contractility in sheep ventricular myocytes

  2019cites this paper
• Advances in the understanding and treatment of sepsis-induced immunosuppression

  2018cites this paper
• The Emperor Has No Clothes? Searching for Dysregulation in Sepsis

  2018cites this paper
• Sepsis: The Road Ahead

  2018cites this paper
• A Role for Hydrocortisone Therapy in Septic Shock?

  2018cites this paper
• Precision medicine as a control problem: Using simulation and deep reinforcement learning to discover adaptive, personalized multi-cytokine therapy for sepsis

  2018cites this paper
• Haptoglobin improves shock, lung injury, and survival in canine pneumonia.

  2018cites this paper
• Protective effects of rutin on lipopolysaccharide-induced heart injury in mice.

  2018cites this paper
• Immune therapy in sepsis: Are we ready to try again?

  2018cites this paper
• Model-based Decision Support for Sepsis Endotypes

  2018cites this paper
• Chronic Critical Illness and Persistent Inflammation: What can we Learn from the Elderly, Injured, Septic, and Malnourished?

  2018cites this paper
• Role of interleukin-3 as a prognostic marker in septic patients

  2018cites this paper
• Effect of Low-Dose Hydrocortisone Therapy in Adult Patients With Septic Shock: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials

  2018cites this paper
• Impact of thrombosis on pulmonary endothelial injury and repair following sepsis.

  2017cites this paper
• A flow cytometric assessment of the lymphocyte immunophenotypes in dogs naturally infected with Babesia

  2017cites this paper
• Bridging the Translational Gap: The Challenges of Novel Drug Development in Critical Care

  2017cites this paper
• From Phantasmagoria to Reality?

  2017cites this paper
• Immunomodulation in Critical Illness: The Quest Continues.

  2017cites this paper
• Stem Cells and Their Immunomodulatory Potential for the Treatment of ARDS

  2017cites this paper
• Treatment of endotoxaemia and septicaemia in the equine patient

  2017cites this paper
• Systemic inflammatory response syndrome, sequential organ failure assessment, and quick sequential organ failure assessment: more pieces needed in the sepsis puzzle.

  2017cites this paper
• Butyrate pretreatment attenuates heart depression in a mice model of endotoxin‐induced sepsis via anti‐inflammation and anti‐oxidation

  2017cites this paper
• Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti‐CD14 antibody and the modified second domain of bikunin improves survival in rabbit sepsis models

  2017cites this paper
• Therapeutic Inhibition of Complement Component C5a in a Mouse Model of Post-traumatic Sepsis

  2017cites this paper
• 67 – Pathogenesis of Fever

  2017cites this paper
• Honokiol Increases CD4+ T Cell Activation and Decreases TNF but Fails to Improve Survival Following Sepsis

  2017cites this paper
• Pathophysiology of Systemic Inflammatory Response Syndrome

  2017cites this paper
• (E)-1,3-diphenyl-1H-pyrazole derivatives containing O-benzyl oxime moiety as potential immunosuppressive agents: Design, synthesis, molecular docking and biological evaluation.

  2016cites this paper
• Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit?

  2016cites this paper
• Bifunctional role of pro-inflammatory cytokines after traumatic brain injury

  2016cites this paper
• Modulation de TREM-1 au cours du l'infarctus du myocarde

  2016cites this paper
• Role of C-reactive Protein and Tumor Necrosis Factor-Alpha in Differentiating between Ventilator-Associated Pneumonia and Systemic Inflammatory Response Syndrome without Infectious Etiology

  2016cites this paper
• Biomarkers of Bronchopulmonary Dysplasia

  2016cites this paper
• Cerebrospinal Fluid Cytokines and Neurotrophic Factors in Human Chronic Pain Populations: A Comprehensive Review

  2016cites this paper
• Interleukin-33 plays an important role in sepsis-induced acute lung injury in mice

  2016cites this paper
• Future of Critical Care Medicine

  2016cites this paper
• The proinflammatory role of HECTD2 in innate immunity and experimental lung injury

  2015cites this paper
• Agent-Based Modeling and Translational Systems Biology: An Evolution in Parallel

  2015cites this paper
• Can biomarkers help us to better diagnose and manage sepsis?

  2015cites this paper
• 55 – Temperature Regulation and the Pathogenesis of Fever

  2015cites this paper
• but not severity of infection in a rat sepsis model improves or worsens survival dependent on the route Neutrophil inhibition with L-selectin-directed MAb

  2015cites this paper
• Plasma Neutrophil Gelatinase-Associated Lipocalin Is Primarily Related to Inflammation during Sepsis: A Translational Approach

  2015cites this paper
• Pattern of soluble CD5 and CD6 lymphocyte receptors in critically ill patients with septic syndromes.

  2015cites this paper
• The association between time to antibiotics and relevant clinical outcomes in emergency department patients with various stages of sepsis: a prospective multi-center study

  2015cites this paper
• Predicting mortality after elective open-heart surgery using midregional-proadrenomedullin: is it time to scalp Acute Physiology and Chronic Health Evaluation IV?

  2015cites this paper
• Characterization of the interaction of staphylococcal enterotoxin B with CD1d expressed in human renal proximal tubule epithelial cells

  2015cites this paper
• Stimulation and Suppression of Innate Immune Function by American Ginseng Polysaccharides: Biological Relevance and Identification of Bioactives

  2015cites this paper
• Protecting the Endothelial Cell Barrier

  2015cites this paper
• The NLRC4 Inflammasome and its Regulation of Liver Disease Pathogenesis

  2015cites this paper
• Immunopharmacology and in fl ammation Tyrosine kinase inhibitor tyrphostin AG 490 reduces liver injury in LPS-induced shock

  2015cites this paper
• Sequestration as the Initial Step in Limiting the Adverse Effects of Pathogen Toxins

  2015cites this paper
• Advances in Sepsis Research.

  2015cites this paper
• Tyrosine kinase inhibitor tyrphostin AG490 reduces liver injury in LPS-induced shock.

  2015cites this paper
• Sepsis biomarkers.

  2015cites this paper
• Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-a (TNF-a) using AZD9773, an anti-TNF-a immune Fab, in murine CLP sepsis

  2014cites this paper
• American Ginseng Modulation of Immune Function and Phytochemical Analysis

  2014cites this paper
• Association between source of infection and hospital mortality in patients who have septic shock.

  2014cites this paper
• Strategies to improve drug development for sepsis

  2014cites this paper